Chemical inhibitors of AGP-8 include a diverse group of compounds that interfere with the protein's function through several distinct mechanisms. Staurosporine and Imatinib, for example, can inhibit AGP-8 by targeting its possible kinase activity. These inhibitors block the ATP binding site of AGP-8, thus preventing any phosphorylation activity that AGP-8 may be involved in. Specifically, Imatinib binds to the tyrosine kinase domain, which would impede AGP-8 if it operates within that capacity. Similarly, LY294002 and Wortmannin can inhibit AGP-8 by obstructing the PI3K/Akt pathway, which is critical for multiple cellular functions. These inhibitors impede the formation of PIP3, a vital secondary messenger in the PI3K pathway, potentially reducing AGP-8 activity that is contingent on this signaling cascade.
Additionally, PD98059 and U0126 serve as inhibitors of the MAPK/ERK pathway, which could be a signaling pathway where AGP-8 has a role. By inhibiting the upstream kinases MEK1 and MEK2, these chemicals prevent the activation of the ERK pathway, which can limit AGP-8's functionality tied to this signaling route. SB203580 and SP600125 are inhibitors targeting the p38 MAPK and JNK pathways, respectively, which are pathways that AGP-8 may be involved in, particularly in cellular responses to stress or cytokines. The inhibition of these pathways can hinder AGP-8's activity in cells by preventing necessary signaling events from occurring. Proteasome inhibitors MG132 and Bortezomib can inhibit AGP-8 by preventing the degradation of regulatory proteins that are responsible for controlling AGP-8's function. This results in the accumulation of such regulatory proteins and indirect inhibition of AGP-8's activity. Lastly, Rapamycin and Trichostatin A act on mTOR signaling and chromatin structure, respectively. Rapamycin inhibits mTOR complexes that AGP-8 may need for activation, while Trichostatin A can alter gene expression patterns of proteins that regulate AGP-8, both leading to functional inhibition of AGP-8.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can inhibit AGP-8 if the protein has kinase activity, by blocking its ATP-binding site, thus preventing phosphorylation processes AGP-8 might be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that, if AGP-8 is part of PI3K/Akt signaling, can inhibit AGP-8's function by preventing the production of PIP3, which is necessary for AGP-8 associated pathway activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an ERK pathway inhibitor that may inhibit AGP-8 by blocking the MAPK/ERK pathway, which could be upstream or downstream of AGP-8 function, thus preventing AGP-8 related signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that potentially inhibits AGP-8 by disrupting the p38 MAPK pathway related to stress responses that AGP-8 could be a part of, hindering AGP-8's functional role. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can inhibit AGP-8 by preventing the degradation of regulatory proteins that control AGP-8 function, leading to the accumulation of such regulatory proteins and indirect inhibition of AGP-8. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, another proteasome inhibitor, can inhibit AGP-8 by similar mechanisms as MG132, potentially leading to altered signaling dynamics that could suppress AGP-8 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can indirectly inhibit AGP-8 if it's part of the mTOR signaling pathway by inhibiting mTORC1 and possibly mTORC2 complexes, which may be required for AGP-8 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, like LY294002, is a PI3K inhibitor that can prevent the phosphorylation and activation of AGP-8 if it's involved in the PI3K/Akt pathway, leading to functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can inhibit AGP-8 by blocking the JNK signaling pathway, which could be essential for AGP-8's role in cellular responses to stress or cytokines. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can inhibit AGP-8 if the protein has tyrosine kinase activity or is part of a pathway regulated by tyrosine kinases, by preventing phosphorylation of the protein or its substrates. | ||||||